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1,25-Dihydroxyvitamin D3-conditioned 
cD11c+ Dendritic cells are effective 
initiators of cns autoimmune 
Disease
Dario Besusso1,2,3 , Louise Saul1,2,3 , Melanie D. Leech1,2,3 , Richard A. O’Connor1,2,3 ,  
Andrew S. MacDonald4 , Stephen M. Anderton1,2,3 and Richard J. Mellanby1,2,3,5*
1 MRC Centre for Inflammation Research, The University of Edinburgh, Edinburgh, UK, 2 Centre for Multiple Sclerosis 
Research, The University of Edinburgh, Edinburgh, UK, 3 Centre for Immunity, Infection and Evolution, The University of 
Edinburgh, Edinburgh, UK, 4 Manchester Collaborative Centre for Inflammation Research, The University of Manchester, 
Manchester, UK, 5 The Roslin Institute, Royal (Dick) School of Veterinary Studies, The University of Edinburgh, Midlothian, UK
Dendritic cells (DC) play a crucial role in regulating T cell activation. Due to their capacity 
to shape the immune response, tolerogenic DC have been used to treat autoimmune 
diseases. In this study, we examined whether 1,25 dihydroxyvitamin D3-conditioned 
bone marrow-derived DC (VitD-BMDC) were able to limit the development of autoim-
mune pathology in experimental autoimmune encephalomyelitis (EAE). We found that 
VitD-BMDC had lower expression of MHC class II and co-stimulatory molecules and 
were less effective at priming autoreactive T cells in vitro. Using our recently described 
BMDC-driven model of EAE, we demonstrated that VitD-BMDC had a significantly 
reduced ability to initiate EAE. We found that the impaired ability of VitD-BMDC to 
initiate EAE was not due to T cell tolerization. Instead, we discovered that the addition 
of 1,25(OH)2D3 to BMDC cultures resulted in a significant reduction in the proportion of 
CD11c+ cells. Purified CD11c+ VitD-BMDC were significantly less effective at priming 
T cells in  vitro yet were similarly capable of initiating EAE as vehicle-treated CD11c+ 
BMDC. This study demonstrates that in vitro assays of DC function can be a poor pre-
dictor of in vivo behavior and that CD11c+ VitD-BMDC are highly effective initiators of an 
autopathogenic T cell response.
Keywords: dendritic cell, vitamin D, experimental autoimmune encephalomyelitis, multiple sclerosis, T cell
inTrODUcTiOn
Dendritic cells (DC) are specialized sentinel cells that bridge the innate and adaptive immune 
response and play a crucial role in shaping the adaptive immune response (1). Depending 
on their activation status, DC can either activate or tolerize T cells. Activated DC upregulate 
co-stimulatory molecules and produce cytokines that drive T cell priming and effector 
differentiation (1). In the absence of activation, antigen presentation by steady-state DC can lead to 
T cell unresponsiveness and tolerance (1).
The ability of DC to tolerize T cells has resulted in the use of tolerogenic autologous DC as 
a treatment for autoimmune diseases (2). This approach is seen as highly attractive since it has 
the potential to limit the pathogenicity of autoreactive T cells without the need for widespread 
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immunosuppression, which is a common side effect of many 
current therapies for autoimmune diseases (2, 3). A commonly 
used approach to generate tolerogenic DC involves the addition 
of immunomodulatory agents alongside GM-CSF to either 
monocyte or bone marrow cultures (2). The addition of the active 
vitamin D metabolite, 1,25 dihydroxyvitamin D3 (1,25(OH)2D3), 
to either murine bone marrow DC (BMDC) (4–6) or human 
monocyte-derived DC cultures (7–9), has been widely used to 
generate DC with a tolerogenic phenotype.
While the generation of clinical grade tolerogenic DC using 
1,25(OH)2D3 has been shown to be feasible (7, 10, 11), the admin-
istration of autoantigen loaded DCs to patients with an ongoing 
autopathogenic T cell response is clearly not without risks. The 
safety profile of tolerogenic DC therapy has been difficult to assess 
in experimental models for a range of reasons, notably due to the 
difficulty of a robustly inducing autoimmunity through the pas-
sive transfer of DC. In experimental autoimmune encephalomy-
elitis (EAE), the widely used rodent model of multiple sclerosis 
(MS), few studies have demonstrated that the passive transfer of 
myelin-loaded DC can promote autoimmune pathology creating 
the impression that the transfer of DC in patients is unlikely to 
result in exacerbation of disease (12–14).
We have recently reported a novel model of BMDC-driven 
EAE in which mice develop a robust monophasic course of EAE 
following the transfer of traceable myelin basic protein (MBP)-
reactive T cells and MBP-loaded, LPS-activated BMDC (15). 
In this study, we sought to understand whether 1,25(OH)2D3-
conditioned BMDC (VitD-BMDC) were able to tolerize naïve 
T cells in  vivo. We initially demonstrated that administration 
of 1,25(OH)2D3 completely protected mice from active EAE, 
whereas it afforded mice administered ex vivo activated T cells 
no protection, suggesting that vitamin D may play an important 
role in modulating the priming of naive T cells in vivo. We 
showed that BMDC generated in the presence of 1,25(OH)2D3 
(VitD-BMDC) were significantly less effective at inducing EAE. 
Surprisingly, this was not due to a tolerizing effect on T cells with 
autopathogenic potential. Instead, we found that the addition of 
1,25(OH)2D3 to bone marrow cultures resulted in a significant 
reduction in CD11c+ cells. Purified CD11c+ VitD-BMDC 
were significantly less effective at priming CD4+ T cells in vitro 
but were similarly effective at initiating EAE as vehicle-treated 
CD11c+ BMDC. This study demonstrates that CD11c+ VitD-
BMDCs are in fact highly effective initiators of an autoaggres-
sive T cell response in vivo, and highlights the fact that in vitro 
priming assays of DC function can be poor predictors of in vivo 
behavior and functionality.
MaTerials anD MeThODs
Mice, antigens, and Tissue culture 
Medium
B10.PLxC56BL/6 and Tg4 CD45.1 mice were bred under specific 
pathogen-free conditions at the University of Edinburgh, and all 
experiments had local ethical approval and were performed in 
accordance with UK legislation. Tg4 mice express a transgenic 
T cell receptor (TCR) recognizing the Ac1-9 peptide of MBP 
in association with I-Au (16). The MBP Ac1-9(4Lys) and a Ac1-
9(4Tyr) analog peptide were obtained from Cambridge Research 
Biochemicals (Cleveland, UK). Tissue culture medium (RPMI 
1640 medium) was supplemented with 2  mM l-glutamine, 
100  U/ml penicillin, 100 μg/ml streptomycin, and 5 ×  10−5 M 
2-ME (all from Invitrogen Life Technologies, Paisley, UK) and 
10% FCS (Sigma-Aldrich, Dorset, UK).
active induction of eae and 1,25(Oh)2D3 
administration
B10.PLxC57BL/6 (CD45.2) mice received 2 ×  106 Tg4.CD45.1 
CD4+ T cells. One day later (day 0), mice received 10 μg of the 
Ac1-9(4Tyr) peptide emulsified in CFA containing 50  μg of 
heat-killed Mycobacterium tuberculosis H37Ra (Sigma-Aldrich, 
Dorset, UK) at a total final volume of 100 μl injected s.c. into the 
hind legs. On the day of immunization and 48 h later, each mouse 
also received 200 ng of pertussis toxin (Health Protection Agency, 
Dorset, UK) in 0.5 ml PBS i.p. Clinical signs of EAE were assessed 
daily with the following scoring system: 0, no signs; 1, flaccid 
tail; 2, impaired righting reflex and/or gait; 3, partial hind limb 
paralysis; 4, total hind limb paralysis; 5, hind limb paralysis with 
partial front limb paralysis; 6, moribund or dead. Two hundred 
nanograms of 1,25(OH)2D3 (Sigma-Aldrich, Dorset, UK) in 
200 μl soybean oil (Sigma-Aldrich, Dorset, UK), or vehicle alone, 
were administered i.p to mice every 48 h from day −1 to day 7 
relative to day of immunization.
generation of Tg4 T effector cells and 
Passive induction of eae
Tg4.CD45.1 splenocytes were cultured at 4 × 106 cells per ml with 
10 μg/ml MBP(Ac1-9), 25 ng/ml rIL-12, 0.5 ng/ml rIL-2 (both 
from R and D systems), and 25 ng/ml rIL-18 (MBL, Nagoya) as 
described previously (17). Cells were harvested after 72 h culture 
and 3 ×  106 blasts were transferred i.v (day 0). On the day of 
cell transfer each mouse also received 200 ng of pertussis toxin 
(Health Protection Agency, Dorset, UK) in 0.5 ml PBS i.p. Clinical 
signs of EAE were assessed as described above. Administration of 
1,25(OH)2D3 was also undertaken as described above.
generation of BMDc, cytokine analysis, 
and Primary Tg4 T cell activation assays
Bone marrow dendritic cells were generated in the presence of 
recombinant GM-CSF (Peprotech, London, UK) for 9  days as 
previously described (18). Briefly, bone marrow was collected 
from tibias of B10.PLxC57BL/6 mice, and clusters within the 
bone marrow suspension were dispersed by vigorous pipetting. 
Cells were seeded into 6 well plates at 2 × 105/ml in 2 ml 10% FCS 
medium with the addition of 20 ng/ml GM-CSF. At day 3, a further 
2 ml of medium containing 20 ng/ml GM-CSF was added to each 
well. At days 6 and 8, 2 ml of culture supernatant was removed 
and replaced with 2 ml fresh culture medium containing 20 ng/ml 
GM-CSF. Vehicle or 1,25(OH)2D3 was added to the BMDC culture 
media at the concentration indicated in the text initially and at 
all subsequent media changes. To activate the BMDC, the cells 
were harvested at day 9 and were re-plated at 2 × 106 BMDC/ml 
with 0.1 μg/ml lipopolysaccharide (LPS) (Sigma-Aldrich, Dorset 
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UK) and 5  ng/ml of GM-CSF with 0.1 μg/ml Ac1-9(4Tyr) for 
an additional 18 h. In some experiments, CD11c+ BMDC were 
separated by FACS sorting prior to overnight stimulation with 
LPS and MBP. Cytokines were measured in BMDC supernatants 
by Flowcytomix simplexes as per manufacturer’s instructions 
(eBioscience, San Diego, CA, USA).
To study the primary activation of Tg4 T cells, varying num-
bers (as stated) of BMDC were cultured with 2 × 104 CD4+ Tg4.
CD45.1+ T cells per well (round bottomed, 96 well plates). The 
CD4+ T cells were purified using microbeads as per manufac-
turer’s instructions (Miltenyi Biotech, Surrey, UK). After 48  h, 
cell proliferation was assessed by the addition of [3H]thymidine 
(PerkinElmer, Cambridge, UK) at 0.5 μCi/well for the last 18 h 
of culture. [3H]Thymidine incorporation was measured using a 
scintillation β-counter (Wallac, Milton Keynes, UK). The results 
are expressed as mean counts per minute (c.p.m.) ±  standard 
error of the mean (SEM) Tg4. T cell production of cytokines (IL-
2, IL-10, IL-17, and IFN-γ) was assessed in culture supernatants 
by ELISA using paired monoclonal antibodies and recombinant 
cytokine standards purchased from BD Biosciences (NJ, USA). 
GM-CSF and TNF-α was detected using GM-CSF Ready-SET-Go 
ELISA (ebioscience, San Diego, CA, USA). IL-2 was measured in 
supernatants after 48 h of culture and IFN-γ, TNF-α, GM-CSF, 
IL-10, and IL-17 were measured after 72 h of culture.
BMDc-Driven eae
B10.PLxC57BL/6 mice received 2  ×  106 Tg4.CD45.1 CD4+ T 
cells. One day later, mice received 2 × 106 LPS-stimulated, MBP 
Ac1-9(4Tyr) pulsed BMDC or CD11c + BMDC in a total volume 
of 100 μl injected s.c (50 μl into each hind leg). On the day of 
BMDC transfer, each mouse also received 200  ng of pertussis 
toxin (Health Protection Agency, Dorset, UK) in 0.5 ml PBS i.p. 
Clinical signs of EAE were assessed daily as described above.
Preparation of Mononuclear cells and 
Facs analysis
Mice with EAE were sacrificed by CO2 asphyxiation, perfused 
with cold PBS and mononuclear cells were prepared from the 
brain and spinal cord as described previously (17). Single-cell 
suspensions were made from the spleen and draining lymph 
nodes, red blood cells were lysed using an ammonium chloride 
buffer (Sigma-Aldrich, Dorset, UK) and the cells were then resus-
pended in FACS buffer (PBS, 2% fetal calf serum, 0.01% sodium 
azide (Sigma-Aldrich, Dorset, UK)). Fc receptors were blocked 
with supernatant from the hybridoma 2.4G2. All antibodies 
were from eBioscience, Hatfield, UK, except where stated; LIVE/
DEAD fixable cell stain (Life Technologies), anti-CD4-PerCP, 
anti-CD4-AF700 (BD Pharmingen, Oxford, UK), anti-CD11c-
FITC, anti-Ki67-PE, anti-CD11b-efluor450, anti-CD45.1-FITC, 
anti-CD44-APC-Cy7, anti-CD80-PE, anti-CD86-APC, anti-
CD62L-SA350, anti-Foxp3-PE, anti-GM-CSF-PE, Armenian 
hamster IgG-PE, and OX-6-FITC (AbD Serotec, Kidlington, 
UK). For intracellular staining in response to peptide, cells 
were resuspended at 1 ×  107/ml in the presence or absence of 
20 μM 4Lys MBP. After overnight culture, 1 μl/ml of brefeldin A 
(e-bioscience, Hatfield, UK, 1000× stock) was added for the last 
4 h of culture. Cells were surface stained prior to processing for 
intracellular staining using proprietary buffers according to the 
manufacturer’s instruction (e-bioscience for transcription factor 
staining or Becton Dickinson for cytokine staining). FACS data 
were collected using LSR Fortessa (BD Biosciences, NJ, USA) and 
analyzed using FlowJo software (Tree Star, Olten, Switzerland).
statistical analysis
Statistical analysis of results was performed using the Mann–
Whitney U test, the two-tailed Student’s t-test, and Fischer’s 
exact test as appropriate. Cytokine concentrations are presented 
as mean concentration ±SEM. Significance was set at p < 0.05.
resUlTs
administration of 1,25(Oh)2D3 is Protective 
against active but not Passive eae
1,25(OH)2D3 has been shown to ameliorate pathology in a wide 
range of EAE models, most notably in mice immunized using 
CFA containing spinal cord homogenate (19), or immunodomi-
nant peptides of myelin oligodendrocyte glycoprotein (MOG), 
or MBP (20–30). Here, we made use of an informative T cell 
transfer model in which non-transgenic host mice are first seeded 
with naïve CD4+ T cells from Tg4 mice expressing a transgenic 
TCR recognizing the Ac1-9 peptide of MBP, prior to immuniza-
tion with the Ac1-9(4Tyr) MBP peptide. These MBP-responsive 
T cells can be distinguished from host cells based on disparate 
expression of CD45 isoforms (CD45.1 defining the donor popu-
lation) (17). The ability to track the pathogenic T cells provides 
a more refined system than previous studies and allows us to 
directly assess the impact of 1,25(OH)2D3 on autoreactive T cells. 
We administered 200 ng 1,25(OH)2D3 every 48 h from the day 
prior to immunization, until 7 days after immunization to ensure 
supplementation with 1,25(OH)2D3 during the majority of the 
priming phase of EAE. 1,25(OH)2D3 completely blocked the 
development of EAE, with none of the 14 mice developing dis-
ease, compared to 14 of the 15 vehicle-treated mice (Figure 1A). 
We analyzed four mice of each group at the peak of disease (on 
day 13) for the presence donor Tg4 T cells within CNS infiltrates 
and in the spleen. There was a significantly greater proportion 
of donor Tg4 cells among the CNS, but not the spleen, CD4+ T 
cells of the vehicle-treated mice (Figure 1B). Thus, 1,25(OH)2D3 
administration impaired the induction of CNS autoimmune dis-
ease in this model, likely by limiting the access of MBP-reactive 
CD4+ T cells to the CNS.
The above finding of no shortage of Tg4 cells in the spleens of 
mice protected from EAE suggested that 1,25(OH)2D3 treatment 
might be able to suppress disease downstream of the activation of 
pathogenic potential in MBP-responsive T cells (e.g., by prevent-
ing their migration to the CNS). Modifying T cell migration to 
the CNS is at the root of two current therapeutics for MS (31, 32). 
We therefore asked whether 1,25(OH)2D3 treatment of host mice 
could prevent pathology driven by the infusion of pre-formed 
encephalitogenic Tg4 effector T cells. As shown in Figure 1C, by 
using previously described conditions for the in vitro activation 
and differentiation of Tg4 cells into pathogenic effectors for 
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infusion into naïve mice (17), we found that the disease course 
was very similar in mice receiving 1,25(OH)2D3 or vehicle, with 
the majority of mice in both groups developing EAE. When 
assessed at day 18 post T cell transfer, there were no differences 
in the total numbers of CD4+ T cells, the numbers of donor Tg4 
T cells, or the frequencies of donor Tg4 T cells within the CNS 
(Figure 1D and data not shown). The ability of 1,25(OH)2D3 to 
protect mice from EAE when actively induced by immunization, 
but not when passively transferred with effector T cells, therefore, 
indicated a primary impact on the initial stages of activation of 
potentially autoaggressive T cells.
BMDc generated in the Presence of 
1,25(Oh)2D3 have a reduced ability to 
Prime autoreactive T cells In Vitro
Dendritic cells are key drivers of naïve T cell activation (1). In 
order to examine the effect of 1,25(OH)2D3 on DC function, we 
investigated the effects of restricting exposure to 1,25(OH)2D3 
solely to those DC. Initial in  vitro experiments showed that 
BMDC generated in the presence of 1,25(OH)2D3 (VitD-BMDC) 
had lower expression of MHC class II, CD40, CD80, and CD86 
than vehicle treatment BMDC (Figure 2A). However, the addi-
tion of 1,25(OH)2D3 to BMDC cultures did not restrict the capac-
ity of BMDC to produce EAE-associated innate cytokines in 
response to LPS stimulation (Figure 2B). Furthermore, there was 
no significant increase in IL-10 production by BMDC exposed 
to 1,25(OH)2D following LPS maturation (p =  0.11, Student’s 
t-test). Nevertheless, these BMDC did show an impaired ability to 
trigger the clonal expansion of naïve Tg4 T cells and to promote 
their production of pro-inflammatory effector cytokines, such 
as IL-17A, IFN-γ, and GM-CSF in vitro (Figure 2C). IL-10 was 
not detectable in the supernatants of either Veh-BMDC or Vit-
BMDC and Tg4 co-cultures (data not shown).
1,25(Oh)2D3-conditioned BMDc have a 
reduced ability to initiate eae
To extend the above in vitro observations to the in vivo setting, 
host mice were seeded with CFSE-labeled naive Tg4 T cells and 
then received BMDC pulsed with Ac1-9(4Tyr) MBP generated 
in presence of either vehicle or 1,25(OH)2D3. Sampling the mice 
3 days after DC injection revealed that the Tg4 cells proliferated 
(as assessed by CFSE-dilution) only in the draining lymph node 
and not in the contralateral lymph node or the spleen. This 
proliferation was markedly less in mice receiving VitD-BMDC 
than in those receiving vehicle-treated DC (Figure 3A). Similar 
experiments using naïve Tg4 T cells that were not loaded with 
CFSE, and sampling lymphoid organs 6 days after DC transfer, 
revealed differences in the lymph nodes that drained the site of 
DC injection. Donor Tg4 cells showed evidence of TCR interac-
tion with their cognate peptide–MHC complex (a CD62LloCD44hi 
phenotype) regardless of whether or not the DC were exposed to 
1,25(OH)2D3. However, the numbers of donor CD4+ Tg4 cells 
present in the draining lymph nodes were lower in mice receiving 
the VitD-BMDC (Figure 3B).
Having determined that 1,25(OH)2D3-exposed DC were less 
effective at priming Tg4 cells in vitro and in vivo, our next step was 
FigUre 1 | administration of 1,25(Oh)2D3 is protective against active, 
but not passive, eae. B10.PLxC57BL/6 hosts were seeded with 2.5 × 106 
Tg4.CD45.1 CD4+ T cells prior to immunization for EAE induction with MBP 
peptide. 1,25(OH)2D3 (200 ng) (n = 14) or vehicle (n = 15) was administered 
as described in Section “Materials and Methods.” (a) Disease course.  
(B) Four mice in each group were sacrificed at day 13 for flow cytometric 
analysis of total CD4+ T cells, and donor CD4+CD45.1+ T cells. Cell 
percentages were compared by a Mann–Whitney U test. Results shown are 
pooled from two independent experiments. EAE was induced in B10.PL 
hosts by transfer of 3 × 106 Tg4.CD45.1 effector T cells. Mice received 
1,25(OH)2D3 (n = 13) or vehicle (n = 12) as described in Section “Materials 
and Methods.” (c) Clinical EAE course. (D) Five vehicle and four 
1,25(OH)2D3-treated mice were sacrificed at day 18 post T cell transfer for 
flow cytometric analysis of total CD4+ T cells, and donor CD4+CD45.1+ 
T cells. Cell numbers and percentages were compared by a Mann–Whitney 
U test. Results shown are pooled from two independent experiments.
FigUre 2 | VitD-BMDc have reduced ability to prime MBP reactive 
T cells in vitro.  BMDC were generated and matured with LPS as described 
in Section “Materials and Methods.” (a) Expression of MHC class II, CD40, 
CD80, and CD86 on Veh-BMDC (black line) or VitD-BMDC (gray shade) 
following overnight maturation without or with LPS. (B) Cytokine levels in 
BMDC supernatants sampled after 18 h culture without and with LPS.  
(c) 2 × 104 Tg4 CD4+ T cells were cultured with LPS-conditioned, 
MBP-pulsed BMDC and assessed for proliferation (thymidine incorporation). 
Concentrations of GM-CSF, IFN-γ, and IL-17 were measured in the 
supernatants after 72 h culture. Data are from one of four experiments giving 
consistent results.
FigUre 3 | VitD-BMDc have reduced ability to initiate eae. (a) B10.PL 
received CFSE-loaded 2 × 106 Tg4.CD45.1 CD4+ T cells 1 day prior to 
injection of 2 × 104 MBP-loaded Veh-BMDC or VitD-BMDC into the left 
hindleg. The spleen and right and left popliteal lymph nodes (PLN) were 
harvested separately and single-cell preparations were made. Plots show 
CFSE-dilution gated on CD45.1+ T cells from the indicated organs. Results 
shown are representative of two independent experiments. (B) B10.
PLxC57BL/6 mice received 2.5 × 106 Tg4.CD45.1 CD4+ T cells 1 day prior 
to injection of 2 × 106 MBP-loaded BMDC. Six days later, lymphoid organs 
were harvested for FACS analysis of total CD4+ and donor CD45.1+ cells. 
Cell numbers and percentages were compared by a Mann–Whitney U test. 
(c) 2 × 106 Tg4.CD45.1 T cells were transferred into B10.PLxC57BL/6 mice 
1 day prior to injection of 2 × 106 LPS-conditioned, MBP-loaded Veh-BMDC 
or VitD-BMDC sc in each hindlimb. Pertussis toxin was administered i.p at 
time of BMDC transfer and 2 days later. Results shown are pooled from three 
independent experiments.
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FigUre 4 | Failure of VitD-BMDc to initiate eae is not due to a 
tolerizing effect on T cells. (a) B10.PLxC57BL/6 mice were administered 
2.5 × 106 CD4 + CD45.1 Tg4 T cells i.v followed by 2 × 106 LPS-
conditioned, MBP-loaded BMDCs s/c in the hindlimb on the following day. 
The draining lymph nodes and spleen were harvested at day 6 and single-cell 
preparations were made. Percentage of Foxp3+ cells in donor CD45.1+ T 
cells from spleen and draining lymph nodes are shown. (B) 2 × 106 
CD4 + CD45.1 Tg4 T cells were transferred into B10.PLxC57BL/6 recipients. 
On the following day, 2 × 106 Veh-BMDC or VitD-BMDC were injected s/c in 
hindlimb. Mice were administered 10 μg Ac1-9(4Tyr) MBP and CFA 6 days 
later. Pertussis toxin was administered i.p on day of CFA administration and 
2 days later. The clinical disease course is shown.
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transfer protocol and, 7 days after DC injection, immunized the 
mice for EAE induction with MBP peptide in CFA. The incidence 
of EAE was equivalent between groups of mice receiving vehicle-
treated DC (4/7) or 1,25(OH)2D3-conditioned DC (6/7). We, 
therefore, found no evidence to support the induction of long-
term Ag-specific unresponsiveness in this model by the use of 
VitD-BMDC (Figure 4B).
addition of 1,25(Oh)2D3 to BMDc  
cultures results in a lower Proportion 
of cD11c+ cells
In light of the failure of VitD-BMDC to tolerize naïve Tg4 T cells 
in vivo, we next investigated whether the inability of VitD-BMDC 
to robustly induce EAE was due to an altered phenotype of the 
BMDC, which were generated in the presence of 1,25(OH)2D3. We 
performed flow cytometry analysis on the BMDC at day 9 and found 
that the addition of 1,25(OH)2D3 to the BMDC cultures resulted 
in a dose-dependent decrease in the proportion of CD11c+ cells 
(Figure 5A). Analysis of the CD11c negative cells demonstrated 
that they were all MHC class II negative. The expression of MHC 
class II, CD40, CD80, and CD86 was also significantly lower on 
CD11c+ cells before and after LPS stimulation (Figure 5B). The 
CD11c+ cells from vehicle and VitD-BMDC cultures were isolated 
by FACS sorting and cytokine production measured following 
overnight stimulation with LPS. Production of cytokines involved 
in activating T cells was similar from both CD11c+ and BMDC 
populations (Figure 5C). Next, we examined whether there was 
a differential ability of vehicle or CD11c+ VitD-BMDC to prime 
Tg4 CD4+ T cells. We discovered that CD11c+ VitD-BMDC were 
much less effective at inducing proliferation and effector cytokine 
production from naïve T cells (Figure 5D).
VitD-cD11c+ BMDc are effective at 
Priming T cells In Vivo and at initiating 
eae
Next, we examined whether CD11c+ VitD-BMDC were as 
effective as CD11c+ Veh-BMDC at priming T cells in vivo. We 
immunized host mice seeded with Tg4 CD4+ T cells with either 
FACS sorted CD11c+ Veh-BMDC or CD11c+ VitD-BMDC 
and harvested spleen and draining lymph nodes 6 days later. We 
found that there was no difference in the number of total or donor 
Tg4 CD4+ T cells or percentage of donor Tg4 cells of total CD4+ 
T cells (Figure 6). There was also no statistical difference in the 
proportion of donor Tg4 CD4+ T cells that were Ki67+ or in 
the proportion of cells that were GM-CSF+ following overnight 
stimulation with MBP (Figure 6).
Finally, we examined whether CD11c+ VitD-BMDC were 
as effective at inducing EAE as CD11c+ Veh-BMDC on a per 
cell basis. We immunized host mice seeded with Tg4 CD4+ T 
cells with either 2 ×  106 FACS sorted CD11c+ Veh-BMDC or 
VitD-BMDC that had been cultured overnight with LPS or 
without LPS. CD11c+ Vit-BMDC that were not LPS matured 
were just as effective at inducing EAE as non-LPS matured, 
CD11c+ Veh-BMDC (Figure 7A). To examine the role of LPS 
further, we next repeated the experiments but matured the FACS 
to confirm the consequence of this on CNS pathology. As shown in 
Figure 3C, the incidence of EAE was significantly higher in those 
mice receiving vehicle-conditioned BMDC (14/20) compared to 
those mice receiving VitD-BMDC (3/20) (Fischer’s exact test, 
p < 0.001). The maximum EAE score was also significantly higher 
in mice receiving Veh-BMDC (median score Veh-BMDC 1.5, 
VitD-BMDC 0. Mann–Whitney U test, p < 0.005).
1,25(Oh)2D3-conditioned BMDc Do not 
Tolerize MBP-reactive T cells
As described above, Tg4 cells showed evidence of TCR ligation 
in vivo in response to 1,25(OH)2D3-conditioned BMDC. This leads 
to significantly reduced pathogenic activity in the Tg4 T cells and, 
instead, might have rendered them unresponsive to subsequent 
activation (i.e., the VitD-BMDC might induce immunological 
tolerance to MBP Ac1-9). This possibility was initially investigated 
by examining the expression of Foxp3, a transcription factor 
expressed in regulatory T cells (33), expression in host and donor 
Tg4 cells 6 days following BMDC transfer. There was no significant 
difference in the proportion of donor Tg4 cells expressing 
Foxp3, indicating that VitD-BMDC did not induce a regulatory 
population of Tg4 cells in vivo (Figure 4A). We next investigated 
whether VitD-BMDC could tolerize T cells through other, non-
Foxp3 mediated, mechanism. We used the above Tg4 then DC 
FigUre 5 | VitD-BMDc have a lower proportion of cD11c+ cells. 
(a) BMDCs were generated in presence of 0, 1, or 10 nM of 1,25(OH)2D for 
9 days. CD11b and CD11c expression was assessed by flow cytometry. 
(B) Expression of MHC class II, CD40, CD80, and CD86 on Veh-BMDC 
(black line) or VitD-BMDC (gray shade) gated on CD11c+ cells following 
overnight maturation without or with LPS. (c) Cytokine production by 
CD11c+ Veh-BMDC (open bar) and CD11c+ VitD-BMDC (black bar) without 
or with overnight LPS maturation. (D) 2 × 104 Tg4 CD4+ T cells were 
cultured with LPS-matured Veh-BMDC (open circle) or VitD-BMDC (black 
circle) for 72 h and assessed for proliferation and production of IFNγ. Data 
are from one of four experiments giving consistent results.
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sorted CD11c+ BMDC with LPS overnight prior to transfer. We 
found that LPS-conditioned CD11c+ VitD-BMDC were again 
similarly pathogenic as LPS-conditioned CD11c+ Veh-BMDC 
(Figure 7B). These data demonstrate that on a per cell basis the 
addition of 1,25(OH)2D3 has no effect on restraining the ability of 
CD11c+ to induce a pathogenic T cell response in vivo. Therefore, 
to examine whether the failure of the unsorted VitD-BMDC to 
induce EAE was simply down to the lower proportion of CD11c+ 
cells, we next immunized host mice with either 1 × 106 or 2 × 106 
LPS-matured CD11c+ VitD-BMDC. This number of cells was 
used as approximately half of the VitD-BMDC were CD11c+ 
(Figure  5A). Only 2 of 12 mice immunized with 1 million 
CD11c+ VitD-BMDC developed EAE compared to 7 of 11 mice 
immunized with 2 million CD11c+ VitD-BMDC (Fisher’s exact 
test, p = 0.036). Furthermore, the median peak disease score was 
also significantly lower (Mann–Whitney U test, median Veh-
BMDC 2.5, median VitD-BMDC 0, p = 0.036) (Figure 7C).
FigUre 6 | VitD-cD11c + BMDc can effectively prime T cells in vivo.  
B10.PLxC57BL/6 mice received 2 × 106 Tg4.CD45.1 CD4+ T cells 1 day 
prior to s/c injection of 1 × 105 MBP-loaded CD11c+ Veh-BMDC or CD11c+ 
VitD-BMDC into the hindlimb. Six days later, spleen and draining lymph 
nodes were harvested for FACS analysis of total CD4+ and donor CD45.1+ 
cells. The total numbers of cells, number of donor Tg4 cells, percentage of 
donor Tg4 cells of total CD4+ cells, percentage of Ki67+ of donor Tg4 cells, 
and percentage of GM-CSF+ donor Tg4 are shown in spleen and DLN. Data 
are from one of two experiments giving consistent results.
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DiscUssiOn
The administration of vitamin D has beneficial properties in a 
range of experimental immunopathological conditions (20–30, 
34) and its clinical translation is currently being evaluated in MS 
(35). Our study revealed that 1,25(OH)2D3 could suppress EAE 
driven by active immunization with MBP autoantigen in CFA, 
but could not suppress the development of passive EAE following 
transfer of pre-formed MBP-responsive effector cells. This implied 
an immunomodulatory effect of 1,25(OH)2D3 that was evident 
early in the activation of the T cells, before they had reached 
the point of being fully differentiated effector T cells. Since DC 
are key initiators of naïve T cell activation in vivo, we examined 
the effects of 1,25(OH)2D3 on DC phenotype and function. We 
found that that VitD-BMDC had lower expression of MHC class 
II, CD80, and CD86, which is consistent with other studies of 
murine and human DC (5, 34, 36–39). By contrast, we found no 
evidence that 1,25(OH)2D3-conditioning could significantly alter 
the ability of BMDC to produce pro-inflammatory cytokines in 
response to LPS. Although the production of EAE-associated 
cytokines by DC remains intact in VitD-BMDC, there was a 
failure to induce T  cell proliferation both in  vitro and in  vivo. 
Importantly, our novel BMDC-driven EAE model allowed us to 
probe the effects of VitD-BMDC on T cells that have the potential 
to initiate autoimmune pathology in  vivo (15). We found that 
VitD-BMDC were rarely able to drive an autopathogenic T cell 
response with only 15% of mice developing EAE compared to 
70% of mice immunized with Veh-BMDC.
Arguably, the most plausible explanation for the failure of 
VitD-BMDC to robustly induce EAE would be the induction of 
T cells with a suppressive phenotype (9, 34, 36, 40, 41), which 
may be associated with enhanced production of IL-10 by BMDC 
conditioned with 1,25(OH)2D3 (36, 38). We found no evidence 
for increased DC IL-10 production, or a switch to a regulatory 
T cell phenotype. Furthermore, T cells exposed to VitD-BMDC 
in  vitro did not produce elevated levels of IL-10, we found no 
increase in Foxp3 expression by transferred Tg4 T cells in vivo 
and, perhaps most tellingly, VitD-BMDC transfer did not render 
mice resistant to the subsequent induction of EAE by immuniza-
tion with the MBP peptide in CFA. This latter observation came 
as something of a surprise, since the induction of antigen-specific 
tolerance in T cells exposed in vivo to weak signals 1 and 2 is a 
basic immunological paradigm (42). It remains possible that the 
ability of the transferred DC to produce innate cytokines prevents 
the establishment of the tolerogenic signaling program within the 
Tg4 T cells, leaving them capable of fully pathogenic function 
upon subsequent strong activation, as we found. Alternatively, 
the subcutaneous administration of the DC may well have been 
insufficient to provide a global tolerogenic stimulus to all Tg4 
T cells within the host mice, as the reduced cell proliferation in 
the draining lymph node after transfer of BMDC would indicate. 
Further studies are required to examine whether 1,25(OH)2D has 
different effects on the subsets of CD11c+MHCclassII +  high 
BMDCs which have been recently discovered (43).
To examine whether impaired ability to prime T cells was the 
cause of the failure of VitD-BMDC to induce robust EAE, we 
FigUre 7 | cD11c+ VitD-BMDc are highly effective at initiating 
eae. 1 × 106 CD4 + CD45.1 Tg4 T cells were transferred into B10.
PLxC57BL/6 recipients. One day later, 2 × 106 MBP-pulsed CD11c+ 
Veh-BMDC or VitD-BMDC, which had been matured overnight either 
without LPS (a) (Veh n = 17, VitD n = 22) or LPS (B) (Veh n = 14, 
n = 11), were injected s/c in hindlimb. Pertussis toxin was 
administered i.p at days 0 and 2 post CD11c+ BMDC transfer. The 
clinical disease course is shown. Disease course is shown from three 
pooled experiments. (c) 1 × 106 CD4 + CD45.1 Tg4 T cells were 
transferred into B10.PLxC57BL/6 recipients. One day later, 2 × 106 
(n = 11) or 1 × 106 (n = 12) MBP-pulsed, LPS-matured CD11c+ 
VitD-BMDC were injected s/c in hindlimb. Pertussis toxin was 
administered i.p at days 0 and 2 post CD11c+ BMDC transfer. The 
clinical disease course is shown. Disease course is shown from three 
pooled experiments.
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performed further phenotyping on VitD-BMDC by flow cytome-
try. We found that the addition of 1,25(OH)2D3 to BMDC cultures 
resulted in a reduction of CD11c+ cells, a finding that is consistent 
with a previous study (44). The CD11c− cells were MHC class II 
negative and were unable to prime T cells in vitro. We discovered 
that the CD11c+ VitD-BMDC were significantly less effective at 
priming T cells in vitro yet were just as effective at initiating EAE 
as CD11c+ Veh-BMDC. When the mice were immunized with 
similar numbers of CD11c+ cells as were present in initial VitD-
BMDC transfers, there was the same failure to robustly initiate 
EAE. This finding demonstrates that the inability of VitD-BMDC 
to robustly initiate EAE is due to the lower number of CD11c+ 
cells present in the VitD-BMDC cultures.
Our data raise important concerns to the developing field of 
DC immunotherapy. In light of the effects of 1,25(OH)2D3 on 
DC phenotype in vitro and in vivo, 1,25(OH)2D3 has been widely 
used to generate tolerogenic DC (2). Tolerogenic DCs have been 
used to prevent and ameliorate autoimmune pathology in a wide 
range of experimental murine autoimmune systems, including 
collagen-induced arthritis, non-obese diabetic mice, and EAE 
models (34, 45, 46). The success of the tolerogenic DC treatments 
in experimental systems has resulted in their translation to thera-
pies for humans with autoimmune diseases (2). For example, a 
phase 1 trial of tolerogenic DC treatment in patients with type 
1 diabetes has been undertaken (47) and a trial in rheumatoid 
arthritis using 1,25(OH)2D3-conditioned tolerogenic DC is ongo-
ing (11). 1,25(OH)2D3-conditioned monocyte-derived DCs from 
MS patients have been shown to induce hyporesponsiveness in 
myelin-responsive T cells in vitro, a finding that has fueled inter-
est in the development of tolerogenic DC therapies for MS (48). 
However, it is important to acknowledge that the approaches 
used to generate many of the tolerogenic DC which have been 
used clinically are not exactly the same as the BMDC generation 
methodology used in this study.
Although tolerogenic DCs appear to be a promising 
immunotherapy, the administration of autoantigen-loaded DC 
is not without risk of side effects, particularly regarding their 
potential to further activate autoreactive T cells. The safety of 
tolerogenic DC has been difficult to assess since there have been 
few studies that have robustly demonstrated that a transfer of ex 
vivo generated DC can initiate autoimmunity. Although previous 
studies have attempted to use BMDC to induce EAE, no such 
model has been adopted widely (12–14). This has resulted in the 
impression that the transfer of ex vivo-generated DC is unlikely 
to generate an autopathogenic T cell response.
Our recently described BMDC-induced EAE model has 
allowed us, for the first time, to examine the effects of 1,25(OH)2D3 
on BMDC function in a model where BMDC can robustly induce 
EAE. Our results demonstrate that conditions that have been 
reported to induce tolerogenic DC in some settings do not always 
result in the generation of DC that can tolerize T cells in  vivo 
(2). Indeed, we have shown that the apparent failure of VitD-
BMDC to initiate autoimmune pathology is due to the lower 
number of CD11c+ cells that emerge in BMDC cultures when 
1,25(OH)2D3 is added. Our results caution against the assump-
tion that 1,25(OH)2D3 invariably induces a tolerogenic phenotype 
in BMDC even when they phenotypically and functionally 
show typical features of tolerogenic DC such as lower expres-
sion of co-stimulatory molecules and reduced ability to prime 
T cells in vitro (2). Our study also highlights the difficulties in 
predicting in vivo BMDC function based on in vitro analysis. The 
CD11c+ VitD-BMDC were significantly less effective at initiating 
proliferation and pro-inflammatory cytokine production from 
naïve T cells in vitro yet were equally effective as CD11c+ Veh-
BMDC at initiating clinical CNS autoimmune pathology in vivo. 
The addition of the TLR-4 agonist LPS, which has been used to 
generate tolerogenic DC (11, 49), did not influence this result as 
CD11c+ VitD-BMDC were equally effective as vehicle-treated 
counterparts regardless of whether they were matured with or 
without LPS.
Our finding that 1,25(OH)2D3 can ameliorate active but 
not passive EAE is of interest when considering the possible 
beneficial use of 1,25(OH)2D3 in relapsing-remitting MS. First, 
by analogy with the inability of 1,25(OH)2D3 to modulate pas-
sive EAE, it seems unlikely that 1,25(OH)2D3 would affect the 
autoimmune (T cell) component of a relapse, in which fully 
activated effectors would be expected to be at play. Second, if a 
relapse provoked by reactivation of myelin-responsive memory 
T cells is dependent on presentation of the autoantigen by 
DC or other antigen-presenting innate immune cells, then 
1,25(OH)2D3 might be able to limit this. However, our study 
demonstrates that if 1,25(OH)2D3 administration impairs the 
ability of BMDC to drive pro-inflammatory cytokines from 
T cells, this may not be sufficient to limit CNS autoimmune 
pathology. Third, given the unpredictable timing of MS 
relapses, and our observation that pathogenic activity was not 
irretrievably lost by the T cells that remained in mice receiving 
1,25(OH)2D3-conditioned DC, the prediction might be that 
long-term use of 1,25(OH)2D3 administration would be the 
option most-likely to succeed.
In summary, our data demonstrate that VitD-BMDC have a 
greatly reduced ability to initiate EAE. However, this was not due 
to their ability to induce tolerance in autoreactive T cells. Rather, 
it was due to the reduced numbers of CD11c+ cells that were 
present in VitD-BMDC populations since sorted populations of 
CD11c+ VitD-BMDC were equally as effective at initiating EAE. 
Our study highlights the difficulties of predicting in  vivo DC 
function based on in  vitro assays and demonstrates the potent 
ability of CD11c+ VitD-BMDC to drive an autopathogenic T cell 
response.
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